<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B9F6C57A-5EA9-4585-A0A7-7E08ADD4EE0E"><gtr:id>B9F6C57A-5EA9-4585-A0A7-7E08ADD4EE0E</gtr:id><gtr:name>Temple University</gtr:name><gtr:address><gtr:line1>1801 North Broad Street</gtr:line1><gtr:postCode>PA 19122</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Biosciences</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B9F6C57A-5EA9-4585-A0A7-7E08ADD4EE0E"><gtr:id>B9F6C57A-5EA9-4585-A0A7-7E08ADD4EE0E</gtr:id><gtr:name>Temple University</gtr:name><gtr:address><gtr:line1>1801 North Broad Street</gtr:line1><gtr:postCode>PA 19122</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9D74DB9E-54C8-4520-A641-8426415CAB37"><gtr:id>9D74DB9E-54C8-4520-A641-8426415CAB37</gtr:id><gtr:firstName>Clare</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C8781D80-900D-4EB0-BC88-B885D37E824A"><gtr:id>C8781D80-900D-4EB0-BC88-B885D37E824A</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Bruce</gtr:otherNames><gtr:surname>Richardson</gtr:surname><gtr:orcidId>0000-0002-7233-3950</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8BAC5481-A8EC-4A79-BF12-86AE6CF8B494"><gtr:id>8BAC5481-A8EC-4A79-BF12-86AE6CF8B494</gtr:id><gtr:firstName>Josh</gtr:firstName><gtr:surname>Dixey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/37658EFB-2266-41D5-9A93-C64546258E84"><gtr:id>37658EFB-2266-41D5-9A93-C64546258E84</gtr:id><gtr:firstName>Bruce</gtr:firstName><gtr:surname>Caterson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CD15E74A-739D-48DD-9286-3BFA8E979C40"><gtr:id>CD15E74A-739D-48DD-9286-3BFA8E979C40</gtr:id><gtr:firstName>C</gtr:firstName><gtr:surname>Dent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/98DC3C8D-EC19-4226-BF12-B9E9E2557B50"><gtr:id>98DC3C8D-EC19-4226-BF12-B9E9E2557B50</gtr:id><gtr:firstName>Sally</gtr:firstName><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B7E409B5-A5D1-4E66-86C8-48A751D901BA"><gtr:id>B7E409B5-A5D1-4E66-86C8-48A751D901BA</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800248"><gtr:id>622AE1A5-7921-4185-BBAE-197C57463625</gtr:id><gtr:title>Biomarkers of Musculoskeletal Diseases: diagnosis &amp;amp; treatment of arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800248</gtr:grantReference><gtr:abstractText>At present there are no biomarkers available that can definatively diagnose arthritis or measure the usefulness of many different treatment approaches that are available to help slow the progression of the disease and thereby improve the quality of life of the patient. Indeed, at present there are no means available to diagnose and distinguish between early stage rheumatoid arthtritis and early stage osteoarthritis; if this latter point could be achieved there would be substantial costs savings to the national health care providers in most countries worldwide. The objective of this proposal is to evaluate the capabilities of a panel of biomarker assays to detect different types of tissue breakdown or synthesis products in the blood, joint fluid and urine in large numbers of a medically well-characterised groups of patients with different stages in the progression and types of arthritic disease. These data will then be analysed for different patterns of expression of these substances with a view to identifying specific fingerprints of their occurrance that can be used in clinical trials, to diagnose different disease subtypes and also monitor the benefits of different treatment strategies. After these assays have been developed and validated using MRC funding these technologies will be transferred to an industrial partner so that they can become commercially available to hospitals and research institutions for use in clinical diagnosis and monitoring of treatments as well as for new drug discovery initiatives for treatment of arthritic diseases.</gtr:abstractText><gtr:technicalSummary>The objectives of this proposal are to perform basic biomedical research (i.e. experimentation, development and validation), centred at Cardiff and Keele Universities, for the production and commercialisation (by our industrial partner, MD Biosciences) of robust ELISA kits that quantify body fluid biomarker expression patterns for numerous studies examining the aetiogenesis of degenerative joint diseases in humans. This proposal will focus on developing assays targeting proteoglycan analytes, matrix proteases and their degradation products. The assays to be developed and validated are: (i) new ELISAs that detect and quantify differences in keratan sulphate (KS) sulphation patterns on ?old? versus ?new? KS synthesised and released in different degenerative joint diseases and at different stages of the disease process; (ii) a new ELISA that quantifies the occurrence of aggrecanase-generated aggrecan analytes in biological fluids with an application to an ongoing clincal trial. Additional ELISAs detecting MMP-generated analytes and total aggrecan analyte will also be developed; (iii) the development of new and further development (for commercialisation) of existing ELISAs that quantify the expression of chondroitin sulphate (CS) sulphation motifs as anabolic or reparative biomarkers in degenerative joint disease; and (iv) new ELISAs that will quantify the presence of the serine proteinase HtrA-1 in synovial fluids. Once validated (using our large cohort of patient samples) ELISAs for established biomarkers (i.e. COMP, HA and CTX11) will also be undertaken. Collectively, the data from these studies will be used to elucidate biomarker expression patterns for use in drug discovery programmes, measuring outcomes of clinical trials, for diagnosis of disease and for measuring the efficacy of surgical, pharmaceutical or nutraceutical interventions.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-13</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>400000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy Reading</gtr:department><gtr:description>University of Reading - Cornea Biomarkers</gtr:description><gtr:id>091AD355-080F-4EDB-80A7-C76D89B5DFA6</gtr:id><gtr:impact>This grant has only just started.</gtr:impact><gtr:partnerContribution>Our collaborators are attempting to produce tissue-engineered corneas for use in patient transplants. We are providing well-characterised antibodies for their use in ELISA-based assays to assess the expression of appropriate biomarkers of corneal development. This data will be used in future publications.</gtr:partnerContribution><gtr:piContribution>Provision of ELISA-based biomarker assays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cardiff School of Biosciences</gtr:department><gtr:description>Arthritis Research UK Biomechanics &amp;amp; Bioengineering Centre</gtr:description><gtr:id>F846263C-B4DD-4617-B0DD-097D36805B66</gtr:id><gtr:impact>Obtaining preliminary data for submission of new grant applications.</gtr:impact><gtr:partnerContribution>We have preliminary data on biomarker assays that have and will be used in new grant applications</gtr:partnerContribution><gtr:piContribution>We are both consultants and collaborators for this Centre Grant. We share patient samples and provide antibodies for biomarker and other analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Kolling Institute</gtr:department><gtr:description>Novel methods for studying proteoglycan metabolism in Tissues.</gtr:description><gtr:id>951ABA7A-2372-44BE-97BF-256C8FF0732E</gtr:id><gtr:impact>Submission of an application for a Project Grant from Arthritis Research UK.</gtr:impact><gtr:partnerContribution>Since returning from my 3 month sabbatical I have submitted a Project Grant application to Arthritis Research UK using data collected on this mini-sabbatical.</gtr:partnerContribution><gtr:piContribution>Together we developed new ways (CNBr hydrolysis) of solubilising all/most of the proteoglycans from very collagenous musculoskeletal tissues (e.g. tendon) and developed ways to identify biomarker patterns as their metabolism changes with health and disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Kolling Institute</gtr:department><gtr:description>The glycobiology of the stem/progenitor cell niche</gtr:description><gtr:id>AACFD1EC-4DD6-4972-9F83-9185831798CE</gtr:id><gtr:impact>Preparation of papers and the submission of a grant application to the Mizutani Foundation, Japan</gtr:impact><gtr:partnerContribution>Papers in preparation and submission of a grant application to the Mizutani Foundation in Japan.</gtr:partnerContribution><gtr:piContribution>Preliminary studies on developing musculoskeletal tissues using monoclonal antibodies that recognise chondroitin sulphate sulphation motifs to determine their specific expression patterns during development and ageing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Temple University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Dr Nancy Pleshko - ST-IRIS applications to identifying Cartilage Repair biomarkers</gtr:description><gtr:id>45753663-00D3-4172-B310-A41B0042045E</gtr:id><gtr:impact>Have obtained preliminary data for use in new grant applications and plan to prepare data for publication.</gtr:impact><gtr:partnerContribution>Provision of preliminary data for use in new grant applications.</gtr:partnerContribution><gtr:piContribution>Oswestry provides well-characterised clinical patient samples for analyses using these novel infra-red applications.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Nutraceutical Lectures</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>C7024B50-1490-4110-BC74-B63A55953EBC</gtr:id><gtr:impact>Lectures to audiences of 50 - 100 to discuss the pros and cons of dietary nutraceutical supplements for treatment of musculoskeletal diseases.

Lots of questions on the biological mechanisms underlying the use of nutraceutical supplements to prevent or slow down the course of musculoskeletal diseases.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nuffield &amp; GCSE Work experience students</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>9B600A17-7EE7-4A7F-BF4B-688740FD09B7</gtr:id><gtr:impact>Students got experience at state of the art research methods related to their future academic goals.

They worked in an active biomedical research lab.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Local Schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>27CB1E7B-CCAC-4391-AD2E-FEF321E558E9</gtr:id><gtr:impact>Sparked interesting questions and discussion regarding current medical research.

Students came to visit the Oswestry Research labs.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>League of Friends - Wales</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>5BB54428-37ED-4699-BC5B-32243989B279</gtr:id><gtr:impact>20 -50 audiences: Lay description of ongoing medical research projects.

These meetings afford an opportunity for the lay public to find out more about current biomedical research in the area of musculoskeletal diseases.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lectures to Health Professionals</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>51758F27-C88E-42F1-9555-5400235969BC</gtr:id><gtr:impact>20-50 MSc Physiotherapists - they get a better understanding of molecular events that lead to musculoskeletal diseases.

Good questions asked at the end of the lectures and hopefully they get a better understanding of molecular mechanisms underpinning the onset and treatment of musculoskeletal diseases.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Education day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>04B01C38-EAC3-4C8A-9BA6-65D0582851ED</gtr:id><gtr:impact>~50 school children (mostly sixth formers who were interested in a career in science) attended an Open Day organised by 3 staff in the hospital, including one of the grant holders.
Lectures and practical sessions were organised throughout the researh laboratories.

The day was prompted by a scheme run by the Pathological Society but it proved very sucessful with pupils attending from ~6 local schools and sixth form colleges.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>625000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Tissue Engineering Centre (&amp;pound;6m across four centres - &amp;pound;2.5m ARUK/&amp;pound;3.4m HEIs)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>66EF1B32-8A27-410F-B195-EFDA8901546D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Charles Wolfson Studentship - Stem cell biomarkers in Disc</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Charles Wolfson Charitable Trust</gtr:fundingOrg><gtr:id>0F02E321-A438-4042-8D5D-10C7B0E60363</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>825000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Tissue Engineering Centre (&amp;pound;6m across four centres - &amp;pound;2.5m ARUK/&amp;pound;3.4m HEIs)</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for Wales (HEFCW)</gtr:fundingOrg><gtr:id>CF3BB0F4-A7DB-4440-91DD-4A106B00B69A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>182437</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK - CS/DS as stem cell niche biomarkers</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>ED97D33A-CFE1-4644-A969-C6930989D32B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Havemeyer Foundation -Biomarkers for Musculoskeletal Diseases</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9D4F35E6-32AA-4988-8A1A-68654C96AD37</gtr:id><gtr:impact>Collectively, the contributors to this meeting were set the task of identifying and validating a variety of potential biomarker for musculoskeletal disease where there is a great deal of need for their use in clinical trials etc.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>2014 Havemeyer Symposium on Equine Musculoskeletal Tissue Biomarkers</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B7EF54ED-8F4E-4023-A6C6-47FD5DD1AEB9</gtr:id><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>CNBr cleavage hydrolyses most if not all extracellular matrix proteins. Thus, CNBr was used to hydrolyse various different proteoglycans from musculoskeletal tissues with high collagen contents; e.g. tendons. This method allows quantitative analyses of metabolic changes in these molecules in health and disease.</gtr:description><gtr:id>594D8DDB-789C-4736-9DC8-0C44C65B6635</gtr:id><gtr:impact>in the past, the use of chemical extraction procedures (e.g. guanidine HCl extraction) only allowed one to analyse changes in the metabolism of selected proteoglycan population in highly collagenous tissues. Our new method allows this to be done on most if not all of those present in a given tissue.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Use of CNBr hydrolyses to analyse proteoglycan metabolism.</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Biochemical maturation was performed on one of our existing monoclonal antibodies (BC-3) to increase its affinity and then potential use in liquid phase biomarker assays; e.g. ELISAs. Ely Lilly have now produced an antibody (BC-3-C2) that has several orders of magnitude higher affinity than our original mAb BC-3.</gtr:description><gtr:id>E3F7A3A7-00AB-4BC1-A5C9-684A95C8C576</gtr:id><gtr:impact>Researchers at Ely Lilly have now published work showing that this new 'matured' monoclonal antibody can be used in ELISA-based assays to detect aggrecanase-generated analytes (with the neoepitope ARG...) in synovial fluids, sera and urine from patients suffering a variety of different arthritic diseases.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>BC-3-C2</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>MesoScale Diagnostics have developed and commercialised a very sensitive assay system for multiplex assays of body fluids (sera/plasma, synovial fluid &amp;amp; urine) as well as tissue samples. To date we have tested several of our mAbs in this system and the results look very promising for the development of new assays.</gtr:description><gtr:id>C60D2E47-485F-404A-B16C-EB2973F137F9</gtr:id><gtr:impact>This new technology will provide very sensitive assay procedures where we can analyse large numbers of patient samples for different analyte compositions and thereby obtain &amp;quot;finger prints&amp;quot; or &amp;quot;signatures&amp;quot; of analyte patterns that can be used in disease diagnosis and/or determning the efficacy of treatments (therapeutic or clinical) for patients.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MesoScale Diagnostics (MSD) Assay methods</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of biomarkers to quantify live cell morphology</gtr:description><gtr:id>1E09D5A3-C6F2-49A5-93D3-2EE4F5423BC0</gtr:id><gtr:impact>Preliminary results for future research and submission of grant applications.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Chipman - live cell quantification</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D1660EA-72AA-44F8-AB9B-05E54B9AEF89"><gtr:id>0D1660EA-72AA-44F8-AB9B-05E54B9AEF89</gtr:id><gtr:title>Biochemical composition and turnover of the extracellular matrix of the normal and degenerate intervertebral disc.</gtr:title><gtr:parentPublicationTitle>European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/95f534485141aa88f39174021ab0ba74"><gtr:id>95f534485141aa88f39174021ab0ba74</gtr:id><gtr:otherNames>Sivan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0940-6719</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEE29626-7CE7-4354-9D18-0A1FFBBF0D50"><gtr:id>FEE29626-7CE7-4354-9D18-0A1FFBBF0D50</gtr:id><gtr:title>Viability, growth kinetics and stem cell markers of single and clustered cells in human intervertebral discs: implications for regenerative therapies.</gtr:title><gtr:parentPublicationTitle>European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3caab22aad47c553636b7980fd7e75a7"><gtr:id>3caab22aad47c553636b7980fd7e75a7</gtr:id><gtr:otherNames>Turner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0940-6719</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7EE7B61-B742-4753-9D5E-F003501C8CDF"><gtr:id>B7EE7B61-B742-4753-9D5E-F003501C8CDF</gtr:id><gtr:title>ADAMTS-4_v1 is a splice variant of ADAMTS-4 that is expressed as a protein in human synovium and cleaves aggrecan at the interglobular domain.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f8a8647b3f3a92d258b6e5b9d7a82db"><gtr:id>1f8a8647b3f3a92d258b6e5b9d7a82db</gtr:id><gtr:otherNames>Wainwright SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8694CFD7-0698-4C95-9369-42BCA3C9F165"><gtr:id>8694CFD7-0698-4C95-9369-42BCA3C9F165</gtr:id><gtr:title>Expression of glycosaminoglycan epitopes during zebrafish skeletogenesis.</gtr:title><gtr:parentPublicationTitle>Developmental dynamics : an official publication of the American Association of Anatomists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e5cc485e966650112d54661656e4cc3"><gtr:id>3e5cc485e966650112d54661656e4cc3</gtr:id><gtr:otherNames>Hayes AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-8388</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E819516-F9D7-4601-B0D3-C905FC343C26"><gtr:id>2E819516-F9D7-4601-B0D3-C905FC343C26</gtr:id><gtr:title>Chondroprotective and anti-inflammatory effects of sesamin.</gtr:title><gtr:parentPublicationTitle>Phytochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6cb729d2cd1b56203ab701983cda3e2f"><gtr:id>6cb729d2cd1b56203ab701983cda3e2f</gtr:id><gtr:otherNames>Phitak T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89F008B7-9A2B-4F1E-A6D4-0C6C901FAA5D"><gtr:id>89F008B7-9A2B-4F1E-A6D4-0C6C901FAA5D</gtr:id><gtr:title>International Cartilage Repair Society (ICRS) Recommended Guidelines for Histological Endpoints for Cartilage Repair Studies in Animal Models and Clinical Trials.</gtr:title><gtr:parentPublicationTitle>Cartilage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8aa997e65e43aea7494fd0b734f888ef"><gtr:id>8aa997e65e43aea7494fd0b734f888ef</gtr:id><gtr:otherNames>Hoemann C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1947-6035</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/746113FD-BA7D-43F9-A640-FFC585DBD901"><gtr:id>746113FD-BA7D-43F9-A640-FFC585DBD901</gtr:id><gtr:title>Fell-Muir Lecture: chondroitin sulphate glycosaminoglycans: fun for some and confusion for others.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d21c3aa5afc8c3beb9d441400f4d587a"><gtr:id>d21c3aa5afc8c3beb9d441400f4d587a</gtr:id><gtr:otherNames>Caterson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/534152E1-4F13-4B08-8EF9-C24E8A32A7DF"><gtr:id>534152E1-4F13-4B08-8EF9-C24E8A32A7DF</gtr:id><gtr:title>Differential relative sulfation of Keratan sulfate glycosaminoglycan in the chick cornea during embryonic development.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2e9f3ec28ace0ccfc5c642b87d4b3f08"><gtr:id>2e9f3ec28ace0ccfc5c642b87d4b3f08</gtr:id><gtr:otherNames>Liles M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38A9FF97-501F-4D0C-8DAC-1238C6D55FB4"><gtr:id>38A9FF97-501F-4D0C-8DAC-1238C6D55FB4</gtr:id><gtr:title>Changes in the metabolism of chondroitin sulfate glycosaminoglycans in articular cartilage from patients with Kashin-Beck disease.</gtr:title><gtr:parentPublicationTitle>Osteoarthritis and cartilage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a4d16be0cd1e126b99a33348bf7e2c6c"><gtr:id>a4d16be0cd1e126b99a33348bf7e2c6c</gtr:id><gtr:otherNames>Luo M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1063-4584</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1522C8DC-8511-4CDC-B145-B7A9B82F6C0F"><gtr:id>1522C8DC-8511-4CDC-B145-B7A9B82F6C0F</gtr:id><gtr:title>Proteoglycan metabolism, cell death and Kashin-Beck disease.</gtr:title><gtr:parentPublicationTitle>Glycoconjugate journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8a46f3752fd4026773cf1b531707cbf"><gtr:id>b8a46f3752fd4026773cf1b531707cbf</gtr:id><gtr:otherNames>Li S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0282-0080</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3121B5AA-F784-46A6-83CF-448A58BC18A8"><gtr:id>3121B5AA-F784-46A6-83CF-448A58BC18A8</gtr:id><gtr:title>Spinal deformity in aged zebrafish is accompanied by degenerative changes to their vertebrae that resemble osteoarthritis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e5cc485e966650112d54661656e4cc3"><gtr:id>3e5cc485e966650112d54661656e4cc3</gtr:id><gtr:otherNames>Hayes AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5812DD64-D80F-4C90-B85B-C29069F9C3F9"><gtr:id>5812DD64-D80F-4C90-B85B-C29069F9C3F9</gtr:id><gtr:title>A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs.</gtr:title><gtr:parentPublicationTitle>European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccd67eaa410f1dafd57772937ce7d30c"><gtr:id>ccd67eaa410f1dafd57772937ce7d30c</gtr:id><gtr:otherNames>Brown S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0940-6719</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D0A4FEF-29AE-4C52-8121-6539696CB3BB"><gtr:id>9D0A4FEF-29AE-4C52-8121-6539696CB3BB</gtr:id><gtr:title>ADAMTS-4 activity in synovial fluid as a biomarker of inflammation and effusion.</gtr:title><gtr:parentPublicationTitle>Osteoarthritis and cartilage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0061725cba620664df0b93abfff78c48"><gtr:id>0061725cba620664df0b93abfff78c48</gtr:id><gtr:otherNames>Roberts S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1063-4584</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B91BD14-59EC-4C36-A237-F45ABA51B2B5"><gtr:id>0B91BD14-59EC-4C36-A237-F45ABA51B2B5</gtr:id><gtr:title>Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7bbef247f8e4750be6a2bd88411d5d9"><gtr:id>d7bbef247f8e4750be6a2bd88411d5d9</gtr:id><gtr:otherNames>Melrose J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8043A55-5B30-4AB0-80B5-61CD023230DC"><gtr:id>B8043A55-5B30-4AB0-80B5-61CD023230DC</gtr:id><gtr:title>Advances in the understanding of tendinopathies: a report on the Second Havemeyer Workshop on equine tendon disease.</gtr:title><gtr:parentPublicationTitle>Equine veterinary journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd3f7bdd77d0a480311e5acfbb11500b"><gtr:id>fd3f7bdd77d0a480311e5acfbb11500b</gtr:id><gtr:otherNames>Smith R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0425-1644</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800248</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>